Bank of America just raised its EUR/USD forecast
On Wednesday, JMP Securities reiterated its Market Outperform rating on Prelude Therapeutics (NASDAQ:PRLD), maintaining a $4.00 price target. The firm’s analysts highlighted the company’s recent fourth-quarter 2024 financial results and corporate updates, including data on PRT3789. According to InvestingPro data, the stock is currently trading near its 52-week low of $0.66, with a market capitalization of $36.46 million. Prelude Therapeutics has two assets progressing through clinical trials, and the initial monotherapy results for PRT3789 showed modest efficacy. The analysts consider the drug a viable candidate for combination therapy.
Prelude Therapeutics ended the quarter with a strong cash position of $133.6 million, with InvestingPro analysis confirming the company holds more cash than debt and maintains a healthy current ratio of 5.3. JMP analysts believe that the company’s stock presents a distinct investment opportunity, estimating an approximately 85% potential downside, with a bear case scenario of $0, and up to 646% potential upside, with a bull case scenario of $5 per share. InvestingPro subscribers have access to 12 additional key insights and comprehensive financial metrics for PRLD.
The analysts are particularly interested in the objective responses observed in patients with upper gastrointestinal tract tumors treated with PRT3789. They anticipate further data in the second half of 2025, which will inform their reassessment of market models. The current outlook for Prelude Therapeutics remains positive, with JMP Securities looking forward to additional results from a larger patient cohort. For a deeper understanding of PRLD’s investment potential, investors can access the detailed Pro Research Report available exclusively on InvestingPro, which provides comprehensive analysis of the company’s financial health and growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.